Sotagliflozin Safety and Tolerability Among Renal Transplant Recipients

Phase 2

Completed

• Conditions: Kidney Transplant
• Interventions: Diagnostic Test: eGFR reporting

• Registration Number: NCT05405556
• Lead Sponsor: Martina McGrath, MD

Brief Summary

This is an investigator-initiated, randomized controlled trial in adult KTRs (N=50) with stable allograft function to assess: 1) the reversibility of the expected acute changes in eGFR with sotagliflozin (donated by Lexicon); 2) proportion of patients completing the protocol according to different eGFR reporting strategies (using a predefined algorithm to manage the expected pharmacological effect of sotagliflozin on eGFR); 3) safety and tolerability of sotagliflozin.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-05-20
• Study First Submitted QC: 2022-06-01
• Study First Posted: 2022-06-06
• Study Start: 2022-10-17
• Primary Completion: 2024-05-10
• Status Verified: 2024-11
• Study Completion: 2024-11-16
• Last Update Submitted: 2025-02-03
• Last Update Posted: 2025-02-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Adults ≥18 years

• Recipients of kidney transplant with stable eGFR*

• eGFR-creatinine (CKD-EPI 2021) ≥25 mL/min/1.73 m2

• Informed consent

  • Stable eGFR will be ascertained by careful chart review establishing that the patient's current graft has been functioning for at least 12 months post-transplantation, patients have not been treated for acute rejection within the prior 3 months, and a creatinine-based eGFR is stable (two consecutive measurements separated by at least 28 days within 5 mL/min/1.73 m2) and ≥25 mL/min/1.73 m2.

Exclusion Criteria

• Recurrent urinary tract infections (>2 episodes/year or antibiotic prophylaxis)
• Biopsy-proven acute rejection within 12 weeks
• Screening serum potassium >5.5 mmol/L
• Uncontrolled hypertension (systolic blood pressure >180/100 mmHg)
• New York Heart Association (NYHA) Class IV HF
• Myocardial infarction, unstable angina, revascularization procedure (e.g., stent or bypass graft surgery), or cerebrovascular accident within 12 weeks
• History of diabetic ketoacidosis
• Type 1 Diabetes Mellitus
• Hereditary glucose-galactose malabsorption or primary renal glucosuria
• Liver disease (e.g., acute hepatitis, chronic active hepatitis, cirrhosis); Alanine aminotransferase (ALT) levels >2.0 times the upper limit of normal (ULN) or total bilirubin >1.5 times the ULN, unless consistent with Gilbert's disease
• Malignancy within 5 years (exceptions: squamous and basal cell carcinomas of the skin and carcinoma of the cervix in situ, or a malignancy that in the opinion of the investigator is considered cured with minimal risk of recurrence)
• Human immunodeficiency virus antibody positive
• Major surgery within 12 weeks
• Atraumatic amputation within past 12 months of screening, or an active skin ulcer, osteomyelitis, gangrene, or critical ischemia of the lower extremity within 6 months of screening
• Combination use of ACEi and ARB
• Current use of an SGLT2 inhibitor (within 12 weeks prior to randomization)
• Known allergies, hypersensitivity, or intolerance to SGLT2i or its excipients
• Digoxin plasma level >1.2 ng/mL
• Clofibrate, fenofibrate, dronedarone, or ranolazine treatment that has not been at a stable dose in the 30 days prior to screening or randomization, or a dose adjustment is expected
• Received an active investigational drug (including vaccines) other than a placebo agent, or used an investigational medical device within 12 weeks before Day 1/baseline
• Pregnant or breast-feeding or planning to become pregnant or breast-feed during the study
• Women of childbearing potential not willing to use a highly-effective method(s) of birth control, or who are unwilling or unable to be tested for pregnancy
• Any condition that in the opinion of the investigator would make participation not in the best interest of the subject

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Patients and providers only aware of study eGFR values more than 25% below baseline	eGFR reporting	Any study-related eGFR value more than 25% below the baseline measurement will be reported to the patient and treating physician.
Patients and providers aware of all study eGFR values	eGFR reporting	All study-related eGFR measurements will be reported to the treating physician and patient.

Primary Outcome Measures

Name	Time	Method
Reversibility of eGFR changes	16 weeks total	Following 12 weeks of open-label drug treatment, participants will stop drug and be followed for a further four weeks (16 weeks total). Reversibility will be assessed as the proportion of patients who return to baseline eGFR (+/- 10%) by the end of the 4-week off-treatment period.

Secondary Outcome Measures

Name	Time	Method
Proportion of patients successfully completing the full treatment protocol, according to randomized groups	16 weeks total	Following 12 weeks of open-label drug treatment, participants will stop drug and be followed for a further four weeks. The proportion of patients completing the full 16 weeks will be compared according to randomized groups.

Trial Locations

Locations (1)

Brigham and Women's; 🇺🇸 Boston, Massachusetts, United States